New drug hope for rare skin ulcers: guselkumab trial launches
NCT ID NCT06563323
First seen Mar 10, 2026 · Last updated Jun 09, 2026 · Updated 14 times
Summary
This study tests if guselkumab can heal painful skin ulcers in people with pyoderma gangrenosum, a rare condition. Seventeen adults will receive the drug and be checked at 6, 16, and 32 weeks. The goal is complete wound healing without drainage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WOUND HEAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State Dermatology
RECRUITINGColumbus, Ohio, 43215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Oregon Health and Science University
NOT_YET_RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.